Literature DB >> 18224429

Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation.

Krystallenia I Alexandraki1, Christina Piperi, Panayiotis D Ziakas, Nikolaos V Apostolopoulos, Konstantinos Makrilakis, Vassiliki Syriou, Evanthia Diamanti-Kandarakis, Gregory Kaltsas, Anastasios Kalofoutis.   

Abstract

Low-grade systemic chronic inflammation is a very well-known feature of diabetes mellitus (DM). The purpose of this study was the assessment of the proinflammatory cytokine secretion profile in long-standing diabetes along with the presence of features of systemic inflammation. Metabolic parameters and serum high-sensitivity C-reactive protein, interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha levels were determined in 20 patients with type 1 DM and 21 patients with type 2 DM and compared to 34 healthy subjects. The number of cytokine-secreting peripheral blood mononuclear cells (PBMCs), before and after mitogenic stimulation, was also determined in the same groups. Adverse lipid profile, higher levels of inflammatory markers, and higher count of cytokine-secreting cells were observed more prevalently in type 2 diabetics than in controls. After stimulation, the increase in number of cytokine-secreting cells was higher in controls. In conclusion, patients with DM have evidence of low-grade inflammation and abnormal PBMC function that could be related to long-term sequelae, the accelerated atherosclerotic process, and the susceptibility to infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18224429     DOI: 10.1007/s10875-007-9164-1

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  55 in total

1.  Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications.

Authors:  G Targher; L Zenari; L Bertolini; M Muggeo; G Zoppini
Journal:  Diabetes Care       Date:  2001-05       Impact factor: 19.112

2.  Macrophage-released interleukin-1 in patients with type 1 diabetes mellitus.

Authors:  I Sahdev; P Fort; A Herry
Journal:  Acta Paediatr       Date:  1992-11       Impact factor: 2.299

3.  Circulating adipocytokines in non-diabetic and Type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development.

Authors:  F Celi; V Bini; F Papi; E Santilli; M S Castellani; A Ferretti; M Mencacci; M G Berioli; G De Giorgi; A Falorni
Journal:  Diabet Med       Date:  2006-06       Impact factor: 4.359

4.  Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children.

Authors:  A B Erbağci; M Tarakçioğlu; Y Coşkun; E Sivasli; E Sibel Namiduru
Journal:  Clin Biochem       Date:  2001-11       Impact factor: 3.281

5.  Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes.

Authors:  J C Pickup; G D Chusney; S M Thomas; D Burt
Journal:  Life Sci       Date:  2000-06-08       Impact factor: 5.037

6.  Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.

Authors:  V Mohamed-Ali; S Goodrick; A Rawesh; D R Katz; J M Miles; J S Yudkin; S Klein; S W Coppack
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

7.  Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals.

Authors:  M G Netea; N Hancu; W L Blok; P Grigorescu-Sido; L Popa; V Popa; J W van der Meer
Journal:  Cytokine       Date:  1997-04       Impact factor: 3.861

8.  Activated T lymphocytes from patients with high risk of type I diabetes mellitus have different ability to produce interferon-gamma, interleukin-6 and interleukin-10 and undergo anti-CD95 induced apoptosis after insulin stimulation.

Authors:  H Tchórzewski; E Głowacka; M Banasik; P Lewkowicz; M Szałapska-Zawodniak
Journal:  Immunol Lett       Date:  2001-01-15       Impact factor: 3.685

9.  Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus.

Authors:  Flávia Ozorio Pereira; Tânia Silvia Frode; Yara Santos Medeiros
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

10.  An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles.

Authors:  A G Wilson; N de Vries; F Pociot; F S di Giovine; L B van der Putte; G W Duff
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  41 in total

1.  Putative loss of CD83 immunosuppressive activity in long-standing complication-free juvenile diabetic patients during disease progression.

Authors:  Ulana Juhas; Monika Ryba-Stanisławowska; Urszula Ławrynowicz; Małgorzata Myśliwiec; Jolanta Myśliwska
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

2.  Evidence for the link between defective autophagy and inflammation in peripheral blood mononuclear cells of type 2 diabetic patients.

Authors:  Samira Alizadeh; Hossein Mazloom; Asie Sadeghi; Solaleh Emamgholipour; Abolfazl Golestani; Farshid Noorbakhsh; Mohsen Khoshniatnikoo; Reza Meshkani
Journal:  J Physiol Biochem       Date:  2018-04-13       Impact factor: 4.158

3.  Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes.

Authors:  Dongmei Han; Carlos A Leyva; Della Matheson; Davide Mineo; Shari Messinger; Bonnie B Blomberg; Ana Hernandez; Luigi F Meneghini; Gloria Allende; Jay S Skyler; Rodolfo Alejandro; Alberto Pugliese; Norma S Kenyon
Journal:  Clin Immunol       Date:  2011-02-24       Impact factor: 3.969

4.  The Histone Methyltransferase MLL1 Directs Macrophage-Mediated Inflammation in Wound Healing and Is Altered in a Murine Model of Obesity and Type 2 Diabetes.

Authors:  Andrew S Kimball; Amrita Joshi; William F Carson; Anna E Boniakowski; Matthew Schaller; Ronald Allen; Jennifer Bermick; Frank M Davis; Peter K Henke; Charles F Burant; Steve L Kunkel; Katherine A Gallagher
Journal:  Diabetes       Date:  2017-06-29       Impact factor: 9.461

5.  Circulating levels of IL-1B+IL-6 cause ER stress and dysfunction in islets from prediabetic male mice.

Authors:  Christina M O'Neill; Christine Lu; Kathryn L Corbin; Poonam R Sharma; Stacey B Dula; Jeffrey D Carter; James W Ramadan; Wenjun Xin; Jae K Lee; Craig S Nunemaker
Journal:  Endocrinology       Date:  2013-07-08       Impact factor: 4.736

6.  Peptidylarginine deiminase 4: a nuclear button triggering neutrophil extracellular traps in inflammatory diseases and aging.

Authors:  Siu Ling Wong; Denisa D Wagner
Journal:  FASEB J       Date:  2018-06-20       Impact factor: 5.191

Review 7.  Fracture healing under healthy and inflammatory conditions.

Authors:  Lutz Claes; Stefan Recknagel; Anita Ignatius
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

8.  Aerobic exercises alleviate symptoms of fatigue related to inflammatory cytokines in obese patients with type 2 diabetes.

Authors:  Shehab M Abd El-Kader; Osama H Al-Jiffri; Fadwa M Al-Shreef
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

9.  Cyclooxygenase 2, toll-like receptor 4 and interleukin 1β mRNA expression in atherosclerotic plaques of type 2 diabetic patients.

Authors:  Alessandro Baldan; Silvia Ferronato; Silvia Olivato; Giovanni Malerba; Alberto Scuro; Gian Franco Veraldi; Matteo Gelati; Sergio Ferrari; Sara Mariotto; Pier Franco Pignatti; Sara Mazzucco; Macarena Gomez-Lira
Journal:  Inflamm Res       Date:  2014-08-06       Impact factor: 4.575

Review 10.  Altered Expression of Transporters, its Potential Mechanisms and Influences in the Liver of Rodent Models Associated with Diabetes Mellitus and Obesity.

Authors:  Leilei Ma; Lei He; Le Wang; Li Li; Xuena Lin; Guoyu Pan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-06       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.